Baltimore, Maryland 21231


Purpose:

RATIONALE: Vaccines made from DNA or a gene-modified virus may help the body build an effective immune response to kill tumor cells. Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Applying topical imiquimod to the cervix may be an effective treatment for cervical intraepithelial neoplasia. Giving vaccine therapy together with imiquimod may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy and to see how well it works when given with or without imiquimod in treating patients with grade 3 cervical intraepithelial neoplasia.


Study summary:

OBJECTIVES: Primary - To evaluate safety, tolerability, and feasibility of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine and TA-HPV vaccine with or without imiquimod in patients with human papillomavirus (HPV)16-positive grade 3 cervical intraepithelial neoplasia (CIN3). Secondary - To evaluate the effect of this regimen on histology, based on the regression of cervical intraepithelial neoplasia. - To evaluate the feasibility and safety of study immunotherapy in these patients. - To evaluate the quantitative changes in cervical HPV viral load in these patients following study immunotherapy. - To evaluate changes in lesion size. - To evaluate the cellular and humoral immune response to vaccination. - To evaluate local tissue immune response. - To correlate measures of immune response with clinical response. - To correlate measures of immune response with those observed in the preclinical model. - To evaluate if the efficacy of the prime-boost vaccination can be improved with the cervical application of imiquimod. OUTLINE: This is a dose escalation study of TA-HPV vaccine (groups 1-3 only). Patients are assigned to 1 of 5 treatment groups. - Groups 1-3: Patients receive pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine intramuscularly (IM) in weeks 0 and 4 and TA-HPV vaccine IM in week 8. - Group 4: Patients receive topical imiquimod applied to the cervix once in weeks 0, 4, and 8. - Group 5: Patients receive pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine and TA-HPV vaccine as in groups 1-3, and imiquimod as in group 4. Patients experiencing no improvement of their lesions at week 15 undergo standard cone resection of the squamocolumnar junction. If there is either 1) regression of the size of the lesions by colposcopy and/or 2) no CIN3 lesions detected by colposcopy/biopsy and Pap smear and/or 3) significant decrease of HPV viral load, patients are followed until week 28. At that time, loop electrosurgical excision procedure (LEEP) resection is performed if there is a CIN3 lesion detected by colposcopy/biopsy or suspected by Pap smear. Patients undergoing LEEP are followed until week 32. Patients not undergoing LEEP are followed until week 41 to confirm CIN3 regression. Blood and tissue samples are collected periodically to measure immune response via ELISA, determine viral load and identify co-infecting HPV types via reverse-line blotting, and analyze lymphocytes via flow cytometry. PROJECTED ACCRUAL: A total of 36 patients (3 in groups 1 and 2, 12 in groups 3 and 5, and 6 in group 4) will be accrued for this study.


Criteria:

DISEASE CHARACTERISTICS: - Colposcopically and biopsy confirmed grade 3 cervical intraepithelial neoplasia - Human papillomavirus (HPV) 16-positive disease by PCR - Measurable disease after diagnostic biopsy - No concurrent adenocarcinoma in situ of the cervix PATIENT CHARACTERISTICS: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use an effective form of contraception during study treatment - Immunocompetent - No concurrent malignancy, except for nonmelanoma skin lesions - No serious concurrent disorder, including any of the following: - Active systemic infection - Autoimmune disease - Proven or suspected immunosuppressive disorder - Major medical illnesses of the cardiovascular or respiratory system - No evidence or history of cardiac disease, including any of the following: - Congestive heart failure - Symptomatic arrhythmia not controlled by medication - Unstable angina - History of acute myocardial infarction or cerebrovascular accident within the past 6 months - No history of severe allergy including eczema or other exfoliative skin disorder - No active eczema within the past 12 months - No concurrent skin conditions, including any of the following: - Burns - Traumatic or pruritic skin conditions - Open wounds - Unhealed surgical scars - Patients and their close social, sexual, or domestic contacts may not have any of the following active skin diseases: - Psoriasis - Lichen planus - Sever acneiform rash - Impetigo - Varicella zoster - Sepsis - No close social contact with children under 5 years old - No close social or domestic contact with a pregnant woman - No HIV seropositivity - No allergy to eggs PRIOR CONCURRENT THERAPY: - No previous vaccination with vaccinia - No immunosuppressive medication (i.e., steroid therapy or other immunosuppressive/immunomodulating drugs [e.g., cyclosporine]) within the past 2 months - No investigational agent(s) within the past 6 months - No concurrent participation in another experimental protocol


NCT ID:

NCT00788164


Primary Contact:

Principal Investigator
Cornelia L. Trimble, MD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Maria Hom
Phone: 410-502-0512
Email: mhom3@jhmi.edu


Backup Contact:

N/A


Location Contact:

Baltimore, Maryland 21231
United States

Clinical Trials Office - Sidney Kimmel Comprehensive Cancer Ce
Phone: 410-955-8804
Email: jhcccro@jhmi.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.